911359-30-3Relevant academic research and scientific papers
Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors
Smil, David V.,Manku, Sukhdev,Chantigny, Yves A.,Leit, Silvana,Wahhab, Amal,Yan, Theresa P.,Fournel, Marielle,Maroun, Christiane,Li, Zuomei,Lemieux, Anne-Marie,Nicolescu, Alina,Rahil, Jubrail,Lefebvre, Sylvain,Panetta, Anthony,Besterman, Jeffrey M.,Déziel, Robert
scheme or table, p. 688 - 692 (2009/08/15)
In an effort to identify HDAC isoform selective inhibitors, we designed and synthesized novel, chiral 3,4-dihydroquinoxalin-2(1H)-one and piperazine-2,5-dione aryl hydroxamates showing selectivity (up to 40-fold) for human HDAC6 over other class I/IIa HDACs. The observed selectivity and potency (IC50 values 10-200 nM against HDAC6) is markedly dependent on the absolute configuration of the chiral moiety, and suggests new possibilities for use of chiral compounds in selective HDAC isoform inhibition.
BENZODIAZEPINE AND BENZOPIPERAZINE ANALOG INHIBITORS OF HISTONE DEACETYLASE
-
Page/Page column 68; 69, (2010/11/26)
This invention relates to compounds for the inhibition of histone deacetylase More particularly, the invention provides for compounds of formula (I): wherein A, B, D, E, X1, X2, X3, X4 and n are as defined in the specification A method of inhibiting histone deacetylase in a cell, the method comprising contacting the cell with a compound of formula (I), in an amount sufficient to inhibit histone deacetylase, is also disclosed.
INHIBITORS OF HISTONE DEACETYLASE
-
Page/Page column 71-73, (2010/11/24)
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I); wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.
